用一种减毒活的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）候选疫苗进行单剂量鼻内接种可促进保护性粘膜和全身免疫。
A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity.
作者信息
Adam Awadalkareem, Kalveram Birte, Chen John Yun-Chung, Yeung Jason, Rodriguez Leslie, Singh Ankita, Shi Pei-Yong, Xie Xuping, Wang Tian
机构信息
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
出版信息
NPJ Vaccines. 2023 Oct 20;8(1):160. doi: 10.1038/s41541-023-00753-4.
An attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (∆3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of ∆3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the ∆3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest ∆3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2.
先前有报道称，一种具有修饰的病毒转录调控序列且缺失开放阅读框3、6、7和8（∆3678）的减毒严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒可保护仓鼠免受SARS-CoV-2感染和传播。在此，我们报告单剂量鼻内接种∆3678可保护K18-hACE2小鼠免受野生型或变异型SARS-CoV-2攻击。与野生型病毒感染相比，∆3678疫苗接种诱导的肺和全身T细胞、B细胞、IgA和IgG反应水平相当或更高。结果表明，∆3678是一种有吸引力的黏膜疫苗候选物，可增强针对SARS-CoV-2的肺部免疫力。
Zotero 插件